human duo set elisa kits  (R&D Systems)

Journal: Redox Biology

Article Title: C-terminal interleukin 1 alpha (IL-1α) overexpression drives EMT and a vulnerability to ferroptosis in HNSCC

doi: 10.1016/j.redox.2026.104172

Figure Lengend Snippet: Characterization of IL-1α overexpression constructs in Cal27 HNSCC cells. Gene expression (A-C), protein release (D) and protein expression (E-G) of the three IL1A constructs – Full- Length (FL), N-terminal (NT) and C-terminal (CT) in the Cal27 IL-1α-overexpressing cells were analyzed by RT-qPCR, ELISA and Western blot respectively compared to control. GAPDH was used as an endogenous control for PCR analysis (A-C); α-Tubulin was used as the loading control for whole cell lysate and cytoplasmic fraction western blots (E-F); and Lamin B1 was used as the loading control for the nuclear fraction Western blot (G). Bars represent mean ± SEM from n = 3 independent experiments. IL-1α band intensities were normalized to the respective loading controls. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Article Snippet: Cell culture media from IL-1α overexpressed Cal27 cells were collected for analyzing the levels of IL-1α, IL-1β, IL-6, IL-8 or IL-1RA using Human Duo Set ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's protocols.

Techniques: Over Expression, Construct, Gene Expression, Expressing, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Western Blot, Control

Journal: Redox Biology

Article Title: C-terminal interleukin 1 alpha (IL-1α) overexpression drives EMT and a vulnerability to ferroptosis in HNSCC

doi: 10.1016/j.redox.2026.104172

Figure Lengend Snippet: IL-1α overexpression alters expression of IL-1 pathway genes. Gene expression of IL1B (A), IL6 (B), IL8 (C), IL1RN (D), IL1RAP (E) and IL1R1 (F) in the three IL1A constructs – Full-Length (FL), N-terminal (NT) and C-terminal (CT) in Cal27 IL-1αoverexpressing cells were analyzed by RT-PCR using GAPDH as an endogenous control. Protein secretion of IL-1β (G), IL-6 (H), IL-8 (I), and IL1RA (J) in cell culture supernatants was quantified by ELISA with protein concentrations normalized to cell numbers. Whole cell lysates were analyzed for IL-1R1 expression by Western blot using GAPDH as a loading control (K). Bars represent mean ± SEM from n = 3 independent experiments.∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001.

Article Snippet: Cell culture media from IL-1α overexpressed Cal27 cells were collected for analyzing the levels of IL-1α, IL-1β, IL-6, IL-8 or IL-1RA using Human Duo Set ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer's protocols.

Techniques: Over Expression, Expressing, Gene Expression, Construct, Reverse Transcription Polymerase Chain Reaction, Control, Cell Culture, Enzyme-linked Immunosorbent Assay, Western Blot

Journal: iScience

Article Title: Persistent myeloid cell reprogramming despite miltefosine treatment in leishmania-infected macaques

doi: 10.1016/j.isci.2025.113900

Figure Lengend Snippet: Impact of HePC therapy in L. infantum -infected RMs (A) Experimental scheme: Female RMs were inoculated intravenously with 2x10 7 L. infantum parasites/kg. At day 1 post-infection (p.i.), 6 RMs were treated for 21 days by nasogastric gavage with 5 mg/kg of HePC. Blood and PLNs were collected at different time-points p.i. (weeks 0, 1, 2, 3, 4, 5, 9, and 12). RMs were sacrificed at three time points (weeks 5, 9, and 12 p.i., corresponding to weeks 2, 4, and 9 post-HTi). (B-E) Blood samples were analyzed for (B) erythrocytes, (C) hemoglobin, (D) neutrophils, and (E) monocytes. (F-H) Parasite DNA was quantified by qPCR from (F) blood, (G) bone marrow, and (H) peripheral lymph nodes (PLNs) at weeks 2 and 3 p.i. (black circles: L. infantum -infected RMs; gray squares: L. infantum -infected RMs treated with HePC). (I–K) Levels of (I) CXCL13, (J) IL-1Ra, and (K) IP-10 were measured at week 2 p.i. Each point represents one individual RM. Statistical significance was assessed using the Mann-Whitney U test (∗, p < 0.05; ∗∗, p < 0.01).

Article Snippet: ELISA was used to quantify IL-1Ra (Human IL-1ra/IL-1F3, R&D Systems) and CXCL13 (Human CXCL13/BLC/BCA-1, R&D Systems), while CXCL10/IP-10 was quantified by flow cytometry using a LEGENDplex assay (Biolegend) and standards were used for quantification according to the manufacturer’s instructions.

Techniques: Infection, MANN-WHITNEY